NASDAQ:QTNTQuotient Stock Price, Forecast & News

$7.79

+0.34 (+4.56 %)

(As of 05/29/2020 04:00 PM ET)

Add

Compare

Today's Range

$7.35

Now: $7.79▼

$7.82

50-Day Range

$5.36

MA: $7.34▼

$9.25

52-Week Range

$2.39

Now: $7.79▼

$11.30

Volume808,084 shs

Average Volume881,355 shs

Market Capitalization$625.61 million

P/E RatioN/A

Dividend YieldN/A

Beta2.77

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood-group antigens; reagent red blood cells, which enable the identification of blood-group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Quotient.

2.4 Community Rank

Outperform Votes
Quotient has received 290 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Quotient has received 303 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Quotient has received 51.10% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Quotient and other stocks. Vote “Outperform” if you believe QTNT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe QTNT will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Quotient does not currently pay a dividend.
Dividend Growth
Quotient does not have a long track record of dividend growth.

4.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Quotient insiders have bought more of their company's stock than they have sold. Specifically, they have bought $160,400.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 14.20% of the stock of Quotient is held by insiders.
Percentage Held by Institutions
76.50% of the stock of Quotient is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Quotient are expected to grow in the coming year, from ($1.48) to ($1.17) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Quotient is -5.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Quotient is -5.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Quotient has a P/B Ratio of 259.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.41 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Diagnostic substances

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:QTNT

Previous Symbol

CUSIPN/A

CIK1596946

Webwww.quotientbd.com

Phone011-41-22-716-9800

Debt

Debt-to-Equity Ratio9.74

Current Ratio6.43

Quick Ratio5.67

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$29.13 million

Price / Sales21.48

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.03 per share

Price / Book259.67

Profitability

EPS (Most Recent Fiscal Year)($1.92)

Net Income$-105,390,000.00

Net Margins-324.59%

Return on EquityN/A

Return on Assets-52.57%

Miscellaneous

EmployeesN/A

Outstanding Shares80,310,000

Market Cap$625.61 million

Next Earnings Date6/9/2020 (Confirmed)

OptionableOptionable

Receive QTNT News and Ratings via Email

Sign-up to receive the latest news and ratings for QTNT and its competitors with MarketBeat's FREE daily newsletter.

Quotient (NASDAQ:QTNT) Frequently Asked Questions

How has Quotient's stock been impacted by COVID-19 (Coronavirus)?

Quotient's stock was trading at $4.64 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, QTNT shares have increased by 67.9% and is now trading at $7.79. View which stocks have been most impacted by Coronavirus.

When is Quotient's next earnings date?

Quotient is scheduled to release its next quarterly earnings announcement on Tuesday, June 9th 2020. View our earnings forecast for Quotient.

How can I listen to Quotient's earnings call?

Quotient will be holding an earnings conference call on Tuesday, June 9th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Quotient's earnings last quarter?

Quotient Ltd (NASDAQ:QTNT) issued its quarterly earnings data on Thursday, January, 30th. The company reported ($0.37) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.41) by $0.04. The company earned $7.94 million during the quarter, compared to analyst estimates of $7.10 million. View Quotient's earnings history.

Has Quotient been receiving favorable news coverage?

News coverage about QTNT stock has been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Quotient earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutQuotient.

Who are some of Quotient's key competitors?

Some companies that are related to Quotient include Myriad Genetics (MYGN), Intellia Therapeutics (NTLA), Heska (HSKA), Meridian Bioscience (VIVO), Lantheus (LNTH), Oxford Immunotec Global (OXFD), Vermillion (VRML), Nymox Pharmaceutical (NYMX), Riot Blockchain (RIOT), Celldex Therapeutics (CLDX), Trinity Biotech (TRIB), ImmuCell (ICCC), Arca Biopharma (ABIO), GeneNews (GNWSF) and Akers Biosciences (AKER). View all competitors.

What other stocks do shareholders of Quotient own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quotient investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Verastem (VSTM), Gilead Sciences (GILD), Novavax (NVAX), Cidara Therapeutics (CDTX), Dynavax Technologies (DVAX), Ocular Therapeutix (OCUL) and Clovis Oncology (CLVS).

Who are Quotient's key executives?

Quotient's management team includes the following people:

Mr. Franz Walt, CEO & Director (Age 60)
Mr. Jeremy Stackawitz, Pres (Age 44)
Mr. Edward Farrell, Pres (Age 49)
Mr. Christopher J. Lindop, Chief Financial Officer (Age 61)
Mr. John Allan, Corp. Sr. VP & CTO

What is Quotient's stock symbol?

Quotient trades on the NASDAQ under the ticker symbol "QTNT."

Who are Quotient's major shareholders?

Quotient's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Cormorant Asset Management LP (3.94%), Clearbridge Investments LLC (3.80%), TimesSquare Capital Management LLC (3.64%), Morgan Stanley (3.51%), Morgan Stanley (3.51%) and First Midwest Bank Trust Division (0.49%). Company insiders that own Quotient stock include Edward Farrell, Frederick Hallsworth, Jeremy Stackawitz, Life Sciences Maste Perceptive, Perceptive Advisors Llc, Peter Buhler, Prondzynski Heino Von and Roland Boyd. View institutional ownership trends for Quotient.

Which major investors are selling Quotient stock?

QTNT stock was sold by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, Morgan Stanley, Morgan Stanley, Two Sigma Investments LP, and Tudor Investment Corp Et Al. View insider buying and selling activity for Quotient.

Which major investors are buying Quotient stock?

QTNT stock was acquired by a variety of institutional investors in the last quarter, including TimesSquare Capital Management LLC, First Midwest Bank Trust Division, DAVENPORT & Co LLC, Premier Asset Management LLC, Castleark Management LLC, Engineers Gate Manager LP, Assenagon Asset Management S.A., and Clearbridge Investments LLC. Company insiders that have bought Quotient stock in the last two years include Frederick Hallsworth, Life Sciences Maste Perceptive, Perceptive Advisors Llc, Peter Buhler, and Prondzynski Heino Von. View insider buying and selling activity for Quotient.

How do I buy shares of Quotient?

Shares of QTNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Quotient's stock price today?

One share of QTNT stock can currently be purchased for approximately $7.79.

How big of a company is Quotient?

Quotient has a market capitalization of $625.61 million and generates $29.13 million in revenue each year. The company earns $-105,390,000.00 in net income (profit) each year or ($1.92) on an earnings per share basis.

What is Quotient's official website?

The official website for Quotient is www.quotientbd.com.

How can I contact Quotient?

Quotient's mailing address is B1 Business Park Terre Bonne Route de Crassier 13, Eysins Y9, 1262. The company can be reached via phone at 011-41-22-716-9800.

This page was last updated on 5/30/2020 by MarketBeat.com Staff